Community Research and Development Information Service - CORDIS

Results 1 - 10 of 62
Order by: Results/page:
12 3 4 5 6 7 > 
Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.
ID: 634579
Start date: 2015-05-01, End date: 2019-10-31
Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes...
Programme: H2020-EU.3.1.
Record Number: 193299
Last updated on: 2017-06-29
Comparing the effectiveness and safety of additional low-dose glucocorticoid in treatment strategies for elderly patients with rheumatoid arthritis
ID: 634886
Start date: 2015-09-01, End date: 2020-08-31
GLORIA aims to prove that the addition of chronic low dose glucocorticoids (GC) to current antirheumatic therapy is highly cost-effective and safe in elderly patients with rheumatoid arthritis (RA). RA is a frequent (affecting > 2% of the elderly population), painful and...
Programme: H2020-EU.3.1.
Record Number: 193311
Last updated on: 2017-06-23
Elucidating Pathways of Steatohepatitis
ID: 634413
Start date: 2015-05-01, End date: 2019-04-30
Strongly associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM) that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease in the aging population of Europe. NAFLD is...
Programme: H2020-EU.3.1.1.
Record Number: 193284
Last updated on: 2017-06-23
Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes
ID: 633784
Start date: 2015-09-01, End date: 2020-08-31
Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In...
Programme: H2020-EU.3.1.1.
Record Number: 193256
Last updated on: 2017-06-23
Lifecourse biological pathways underlying social differences in healthy ageing
ID: 633666
Start date: 2015-05-01, End date: 2019-04-30
"The dramatic differentials in healthy ageing, quality of life and life expectancy between individuals of different socioeconomic groups, is a major societal challenge facing Europe. The overarching aim of the LIFEPATH project is to understand the determinants of diverging...
Programme: H2020-EU.3.1.1.
Record Number: 193249
Last updated on: 2017-06-23
Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)
ID: 635342
Start date: 2015-10-01, End date: 2019-09-30
Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have different biological processes at the basis of their disease and consequently their prognosis and responses to therapy are also...
Programme: H2020-EU.3.1.
Record Number: 193328
Last updated on: 2017-06-16
Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES)
ID: 634935
Start date: 2015-09-01, End date: 2020-08-31
Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is...
Programme: H2020-EU.3.1.2.
Record Number: 193315
Last updated on: 2017-06-16
PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke
ID: 634809
Start date: 2015-06-01, End date: 2020-05-31
Every year, 1.3 million Europeans have a stroke and one million ultimately die of stroke. One third of stroke patients remain dependent on the help of others. The annual costs for stroke care in Europe are estimated at € 64.1 billion. Stroke incidence increases almost...
Programme: H2020-EU.3.1.
Record Number: 193307
Last updated on: 2017-06-16
Integrating Epidemiology and Experimental Biology to Improve Risk Assessment of Exposure to Mixtures of Endocrine Disruptive Compounds
ID: 634880
Start date: 2015-05-01, End date: 2019-04-30
A large body of evidence supports associations between exposure to anthropogenic chemicals and endocrine disruptive effects, leading to disorders in humans and wildlife. Based on the scientific documentation it is beyond doubt that endocrine disrupting chemicals (EDCs) are of...
Programme: H2020-EU.3.1.1.
Record Number: 193310
Last updated on: 2017-06-16
A multi-center randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease
ID: 634559
Start date: 2015-05-01, End date: 2020-04-30
Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fraction (HFpEF), a highly prevalent disease in the elderly, mostly women population. There is currently no specific, defined treatment for...
Programme: H2020-EU.3.1.
Record Number: 193296
Last updated on: 2017-06-16
12 3 4 5 6 7 > 
List retrieved on: 2017-07-22
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top